Ernexa Therapeutics (ERNAW) Equity Average (2011 - 2026)

Ernexa Therapeutics has reported Equity Average for 16 years, with the latest figure at $4.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 317.93% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (up 317.93% YoY), and the FY2025 full-year result was $2.1 million, up 4.27% from the prior year.
• Equity Average for Q1 2026 stood at $4.6 million, up from $3.0 million in the prior quarter.
• The five-year high for Equity Average was $21.4 million in Q1 2022, with the low at -$27.0 million in Q3 2024.
• Historically, Equity Average has averaged $2.1 million across 5 years, with a median of $3.7 million in 2023.
• Annual changes were most pronounced in 2024 — Equity Average tumbled 853.96% — and 2026, when it surged 317.93%.
• Ernexa Therapeutics' Equity Average stood at $10.5 million in 2022, then tumbled by 72.3% to $2.9 million in 2023, then plunged by 853.96% to -$21.8 million in 2024, then jumped by 113.67% to $3.0 million in 2025, then surged by 55.08% to $4.6 million in 2026.
• The last three Equity Average figures came in at $4.6 million (Q1 2026), $3.0 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.